STUDY QUESTION: Is the chance of a live birth following IVF treatment and fresh embryo transfer affected by early and mid-luteal serum progesterone (P 4 ) levels?
STUDY DESIGN, SIZE, DURATION: Prospective multicenter cohort study of 602 women undergoing IVF treatment. Patients were recruited from four Danish public Fertility Centers from May 2014 to June 2017. The study population was unselected, thus, representing a normal everyday patient cohort. Patients were treated in a long GnRH-agonist protocol or a GnRH-antagonist protocol and triggered for final oocyte maturation with either hCG or a GnRH-agonist. The same vaginal luteal support regimen was applied in all patients.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Serum P 4 levels from the early or mid-luteal phase were correlated to positive hCG and live birth rates (delivery > gestational week 20). Patients were divided into four P 4 groups based on raw data of P 4 serum levels and reproductive outcomes during early luteal phase (P 4 <60 nmol/l, P 4 60-100 nmol/l, P 4 101-400 nmol/l and P 4 >400 nmol/l) and during mid-luteal phase (P 4 <150 nmol/l, P 4 150-250 nmol/l, P 4 251-400 nmol/l and P 4 >400 nmol/l).
MAIN RESULTS AND THE ROLE OF CHANCE:
The optimal chance of pregnancy was achieved with serum P 4 levels of 60-100 nmol/l in the early luteal phase whereas the optimal P 4 level during the mid-luteal phase was 150-250 nmol/l. Below, but most distinctly above these levels, the chance of pregnancy was consistently reduced. With an early luteal P 4 level of 60-100 nmol/l, the chance of a positive hCG-test was 73%, 95% CI: [59, 84] following cleavage stage embryo transfer. In contrast, with P 4 levels >400 nmol/l, the chance of a positive hCG-test was significantly reduced to 35%, 95% CI: [17, 57] , thus, an absolute risk difference of −38%, P = 0.01. A similar negative association between early luteal P 4 and live birth rate was found, although it did not reach statistical significance. During the mid-luteal phase, a P 4 level of 150-250 nmol/l resulted in an optimal chance of live birth: 54%, 95% CI: [37, 70] compared to 38%, 95% CI: [20, 60] with a P 4 Introduction Progesterone (P 4 ) is essential for the secretory transformation of the human endometrium and for the support of early pregnancy. Following ovarian stimulation for IVF treatment, the P 4 profile during the luteal phase is distinctly different from that of the natural cycle (Fauser et al., 2002) .
As the optimal luteal P 4 level following IVF treatment is poorly understood, it is normal practice to supplement the luteal phase with exogenous P 4 after IVF treatment, using a standard regimen without taking ovarian response to stimulation or luteal steroid levels into account. From an early study by Humaidan et al. (2005) , it was clear that a very low luteal P 4 level following fresh embryo transfer has a deleterious effect on the ongoing pregnancy rate. Patients in that study were triggered with a GnRH agonist for final oocyte maturation, followed by a standard vaginal P 4 support, only. This approach resulted in mid-luteal P 4 levels resembling what is seen during the natural cycle (39 nmol/l). The study was terminated prematurely due to a very low clinical pregnancy rate (6%) and an unexpected high early pregnancy loss rate (79%). In the subsequent randomized controlled trials, the luteal phase support after GnRH agonist triggering was supplemented with a small bolus of exogenous hCG to rescue the corpus luteum function (Humaidan et al., 2010 (Humaidan et al., , 2013 . With this adaption of protocol, the subsequent mid-luteal P 4 levels increased to 77-409 nmol/l and ongoing pregnancy rates were comparable to those of the hCG-triggered control groups.
On this basis, the existence of a lower luteal P 4 threshold necessary to induce a normal secretory endometrial development and the establishment of a pregnancy following IVF treatment and fresh embryo transfer seems plausible. Whether an upper P 4 threshold exists remains unexplored. Interestingly, in frozen embryo transfer cycles (FET) recent studies reported a lower as well as a higher threshold for luteal P 4 in terms of reproductive outcomes (Labarta et al., 2017; Alsbjerg et al., 2018) . Moreover, in a study by Yovich et al., looking at 529 single blastocyst transfers in FET/HRT cycles, an optimal range for mid-luteal P 4 of 70-99 nmol/l was reported. Below, but also above this range, the clinical pregnancy rate was significantly reduced by 20% (Yovich et al., 2015) .
The aim of the present study was to explore the impact of early and mid-luteal P 4 levels on the reproductive outcomes following IVF/ICSI treatment in fresh embryo transfer cycles.
Materials and Methods

Study design
Prospective multicenter cohort study based on serum samples from the early and mid-luteal phases of women undergoing IVF treatment.
Study population
Patients were recruited from four different Danish public fertility centers (The Fertility Clinic Skive, The Fertility Clinic Odense University Hospital, The Fertility Clinic Horsens Region Hospital and The Fertility Clinic Herlev Hospital) from May 2014 to June 2017. The study population was unselected, representing the normal everyday patient cohort treated at the clinics. The inclusion criteria, therefore, allowed patients treated in a long GnRH agonist protocol and a GnRH antagonist protocol to participate as well as patients triggered with hCG or a GnRH agonist. All patients were under the age of 41 and with a BMI < 35 kg/m 2 as required by Danish national guidelines for public fertility treatment (Danish Fertility Society Guideline, 2016) . All patients only participated once.
Written and oral information about the study was given to 1482 patients from which 609 persons (41%) declined to participate. The final study population included 602 patients who had an embryo transfer and relevant luteal phase blood samples taken (Fig. 1, flowchart) .
Serum prolactin levels and thyroid-stimulating hormone (TSH) were within the normal range in all patients prior to treatment start. Clinical information regarding age, body mass index, smoking habits, primary diagnosis, antral follicle count and basal FSH/LH levels were obtained prior to treatment by clinical staff.
Ovarian stimulation
Due to the non-interventional nature of this study, treatment choices regarding protocol-and trigger type were made on a case-by-case basis according to patient characteristics and individual assessment.
Patients treated in a long GnRH-agonist protocol were downregulated using daily SC injections of Buserelin (Suprefact ® , Sanofi, Denmark) starting in the mid-luteal phase of the preceding cycle.
Ovarian stimulation commenced after 12-14 days of down-regulation in case of an endometrial thickness <4 mm. (Gardner et al., 2000) . A maximum of two embryos were transferred on either Day 2, 3 or 5 after OPU. The criteria for the day of transfer followed the local laboratory guidelines of the participating clinics.
Luteal phase support
All patients received vaginal luteal phase support in a standard regimen using 300 mg micronized P 4 daily (Lutinus ® , Ferring Pharmaceuticals), starting on the day after OPU. Patients triggered with the GnRHagonist all had a bolus of 1500 IU hCG on the day of OPU. Based on the individual ovarian response to stimulation, some patients received an additional hCG bolus OPU + 5 based on a protocol previously described (Humaidan et al., 2013) . A small fraction of patients (13%) had one bolus of GnRH agonist (Gonapeptyl ® 0.1 mg, Ferring Pharmaceuticals, Denmark) on OPU + 7 based on the individual clinical assessment. Vaginal P 4 administration continued until the day of pregnancy testing (hCG triggering) or until the seventh gestational week (GnRHa trigger).
Blood sampling
For each patient, blood sampling was performed on three occasions: on the day of triggering for final oocyte maturation (or the day before), on the day of embryo transfer (Day 2, 3 or 5) and on the day of pregnancy testing (OPU + 14). After coagulation at room temperature, blood samples were centrifuged, and serum was isolated and frozen immediately at −80°C until analysis. Denmark. All measurements were performed by experienced technicians according to manufacturer's instructions.
Hormone assays
The detection limit for P 4 was 0.6 nmol/l, and the in-house interand intra-assay coefficients of variation were 4.4 and 1.6%, respectively. The detection limit for estradiol was 0.05 nmol/l and the in-house inter-and intra-assay coefficients of variation were 2.8 and 1.6%, respectively. The detection limit for hCG was 1.2 IU/l, and the in-house inter-and intra-assay coefficients of variation were 3.4 and 1.7%, respectively.
Exposure
Due to a known steep increase in P 4 secretion from the early luteal phase towards the mid-luteal phase in the IVF cycle (Hassiakos et al., 1990) , the outcome measures for patients with early luteal P 4 monitoring and patients with mid-luteal P 4 monitoring, are presented separately. Progesterone groups were defined based on raw data of reproductive outcomes and luteal P 4 levels during the early and midluteal phase separately ( Supplementary Fig. S1 ). For objectivity and comparison, estimates were also calculated based on 10/50/90 and 25/50/75 percentiles.
Outcome
The serum β-hCG concentration was determined 14 days after OPU and was considered positive if β-hCG > 10 IU/l. In patients with β-hCG levels between 10 and 45 IU/l, a control β-hCG was performed after 48 h. Clinical pregnancy was defined as the presence of a live fetus within an intrauterine gestational sac at ultrasound examination in gestational weeks 7-8. Early pregnancy loss refers to (i) patients with an insufficient β-hCG value on the day of pregnancy testing (10-45 IU/l), and decreasing β-hCG values towards null in subsequent hCG-controls; (ii) patients with a positive hCG, but no intra-or extrauterine sac visualized on transvaginal ultrasound in gestational weeks 7-8; and (iii) patients with a fetus without visible heartbeat at ultrasound in gestational weeks 7-8. Clinical pregnancy loss was defined as the loss of a viable intrauterine pregnancy up to and including gestational weeks 20 + 0. A live birth was defined as the delivery of a live infant after gestational week 20 + 0. Clinical gestational dating was performed using the day of OPU as gestational week 2 + 0.
Confounding factors
The potential confounders included in the model were chosen a priori based on a Directed Acyclic Graph (DAG) (Supplementary Figs S2 and S3) . DAGs are visual representations of causal assumptions and can help identifying confounding factors that obscure the real effect of the exposure on the outcome (Howards, 2018) . Based on a structured analysis of the DAG, it is possible to identify a minimum, however, sufficient set of covariates to adjust for in the statistical analysis, which will cover all confounding elements. The web application DAGitty (www. dagitty.net) was used to draw and analyze the DAGs.
Statistical methods
Data are presented as percentages for categorical variables and as mean and standard deviation for continuous parametric variables and median and range for continuous non-parametric variables. Differences in categorical variables between P 4 groups were assessed with Pearson's chi-square test or Fishers exact test when appropriate.
Differences in continuous parametric data between the four P 4 groups were assessed using one-way analysis of variance followed by a post hoc pairwise comparison in case of a statistical difference between groups. Kruskal-Wallis test was used in case of non-parametric continuous data.
The correlation between luteal P 4 levels and the final follicle count was tested using a linear regression model. A multiple logistic regression model was used to assess the association between luteal P 4 levels and reproductive outcome. The model included the independent variables maternal age, maternal BMI, study site, final follicle count on the day of trigger (>12 mm) and late follicular P 4 level for estimates of positive hCG, clinical pregnancy and live birth ( Supplementary Fig. S2 ). For estimates of early pregnancy loss adjustment was made for maternal age, maternal BMI, smoking, final follicle count and peak estradiol level on the day of trigger (Supplementary Fig. S3 ). The cut-off for late follicular P 4 (>4.77 nmol/l) was chosen based on the results of earlier studies (Bosch et al., 2010) .
In case of missing data of covariates, patients were omitted from the final regression analysis (43 patients (10%) on Days 2-3 and 11 patients (3%) on Day 5). Patients with missing values were equally distributed across P 4 groups in both cohorts (P = 0.27 and P = 0.25, respectively). No patients were lost to follow-up.
All statistical analyses were performed using STATA version 13, StataCorp LLC, USA.
Ethical approval
All patients gave their written consent prior to study participation. The study was conducted according to the declaration of Helsinki for Medical Research and was approved by the local Ethics Committee of Central Denmark Region. ClinicalTrial.gov registration number NCT02129998.
Results
Demographic data
The population consisted of 602 women undergoing IVF treatment followed by fresh embryo transfer. The overall mean age and BMI of patients were 32.5 ± 4.5 years and 25.0 ± 4.2 kg/m 2 , respectively.
Baseline characteristics of participants are provided in Table I and cycle  characteristics in Table II .
Reproductive outcomes
The overall rate for positive hCG per transfer and live birth rate per transfer in the study was 48% (286/602) and 34% (203/602), respectively. The overall early pregnancy loss rate was 26% (75/286). There was a statistically significant correlation between the final number of follicles and the luteal P 4 level (P < 0.001).
Early luteal P 4 levels and reproductive outcome (n = 432)
As seen from Fig. 2 , the relationship between luteal P 4 levels and reproductive outcomes seems to be non-linear. In the early luteal phase, the optimal P 4 level for a positive pregnancy outcome was between 60 and 100 nmol/l. Below, but most distinctly above this level, the chance of a positive reproductive outcome decreased Baseline characteristics are presented as mean ± SD for continuous parametric data and as median (range) for continuous non-parametric data. Categorical data is presented as percentages (%). *Data on basal FSH levels were missing in 40 patients (7%). Patients with missing data on basal FSH levels were equally distributed across P 4 groups on both Days 2-3 (P = 0.05) and Day 5 (P = 0.91). **Data on basal LH levels were missing in 59 patients (10%). Patients with missing data on basal LH levels were equally distributed across P4 groups on both Days 2-3 (P = 0.17) and Day 5 (P = 0.99). ***P-value describes the comparison between the chosen primary diagnosis category and the combined group of all other primary diagnosis categories. SI conversion factor for P 4 : nmol/l = 3.18 ng/ml. Mean embryo score 432 Mean embryo score 170 SET 1.5 ± 0.6 1.5 ± 0.8 1.4 ± 0.5 1.5 ± 0.6 1.5 ± 0.7 0.990 SET 1.4 ± 0.6 1.4 ± 0.6 1.3 ± 0.6 1.4 ± 0.7 1.5 ± 0.7 0.537 DET 1.7 ± 0.6 1.8 ± 0.5 1.5 ± 0.6 1.8 ± 0.6 1.6 ± 0.5 0.470 DET 1.4 ± 0.5 1.3 ± 0.6 1.7 ± 0.6 2.0 ± 0.0 Descriptive data is presented as mean ± SD for continuous parametric data and as median (range) for continuous non-parametric data. Categorical data is presented as percentages (%).
*P-value describes the comparison between the chosen luteal phase support category and the combined group of all other luteal phase support categories.
SI conversion factor for P4: nmol/l = 3.18 ng/ml.
( Table III ). The clinical impact of different early luteal P 4 levels on the chance of a live birth is demonstrated in Fig. 3 . The risk of an early pregnancy loss decreased with P 4 >100 nmol/l compared to the reference group (Table III) . Dividing the cohort into two groups with P 4 below or above 100 nmol/l, the OR for early pregnancy loss was significantly increased in the low P 4 group compared to the high P 4 group: 3.2, 95% CI: [1. 21, 8.54] .
Using 10/50/90 or 25/50/75 percentiles to define four P 4 groups revealed the same overall pattern for OR for live birth as seen with the a priori chosen P 4 groups presented above, but with less difference between groups (Supplementary Fig. S6 ). Adding smoking to the regression model did not change the estimates significantly (data not shown).
Mid-luteal P 4 levels and reproductive outcomes (n = 170)
In the mid-luteal phase, i.e. OPU + 5, the optimal P 4 range for a successful reproductive outcome was 150-250 nmol/l (Table III) . As seen in Fig. 2 , a similar non-linear pattern for both positive hCG, clinical pregnancy and live birth was found with a negative association between the reproductive outcomes and P 4 levels below and above the optimal range.
The chance of a live birth in different mid-luteal P 4 groups is shown in Fig. 4 . The figure illustrates that for a reference person, the chance of a live birth following blastocyst transfer is 54%, 95% CI: [37, 70%] if the mid-luteal P 4 level is 150-250 nmol/l. In contrast, if the same reference person has a mid-luteal P 4 level >400 nmol/l, the chance of a live birth is reduced to 38%, 95% CI: [20, 60%], thus, an absolute risk difference of -16 percentage points, P = 0.14.
Using 10/50/90 or 25/50/75 percentiles to define four P 4 groups revealed the same overall pattern for live birth as seen with the a priori chosen P 4 groups ( Supplementary Fig. S6 ). Adding smoking to the regression model did not change the estimates significantly (data not shown).
Confounding effects of protocol type, triggering type or luteal phase support
Based on the DAG neither protocol-nor trigger type was included in the final regression model as their possible confounding effects on the association between luteal P 4 and reproductive outcome were already accounted for by the covariates used in the statistical model. Adding trigger type or protocol type to the regression model did not change estimates significantly. Furthermore, the same reproductive pattern was seen when evaluating cycles with different protocol or trigger types separately, thus, precluding effect modification between protocol or trigger type and luteal P 4 levels ( Supplementary Figs S4 and S5) . The same non-linear pattern between luteal P 4 levels and reproductive outcomes was seen when examining Day 2, 3 or 5 separately (data not shown). A minor fraction of patients (13%) had one small bolus of GnRH agonist on OPU + 7. These patients were equally distributed across different P 4 groups (P > 0.05). Omitting these patients from the cohort did not change outcomes significantly (data not shown). Early luteal phase P4 quantifications were performed on OPU + 2 or OPU + 3. Mid-luteal phase P4 quantifications were performed on OPU + 5. *In the crude OR estimates, all 602 patient with embryo transfer were included.
**Due to missing data on the co-variate late follicular P 4 level in 43 patients on OPU + 2-3 and 11 patients on OPU + 5, the final adjusted regression model included 389 and 159 patients in the early luteal phase cohort and in the mid-luteal phase cohort, respectively. Patients with missing data were equally distributed across P 4 groups in both the early luteal phase (P = 0.47) and in the mid-luteal phase (P = 0.25).
***Due to missing data on the co-variate peak E2 level in 47 patients on OPU + 2-3 and 15 patients on OPU + 5, the final adjusted regression model included 385 and 155 patients in the early luteal phase cohort and in the mid-luteal phase cohort, respectively. Patients with missing data were equally distributed across P 4 groups in both the early luteal phase (P = 0.50) and in the mid-luteal phase (P = 0.09).
SI conversion factor for P 4 : nmol/l = 3.18 ng/ml. CI = confidence interval; OPU = day of oocyte pick-up.
Prevalence of low and high luteal P 4 levels
In the early luteal phase, only 4% of patients had P 4 <60 nmol/l and 7% had P 4 >400 nmol/l. In contrast, in the mid-luteal phase, 20% of patients had serum P 4 levels <150 nmol/l and 31% had serum P 4 levels >400 nmol/l. Thus, measured on OPU + 5, 51% of all treated patients had P 4 levels consistent with a reduced chance of pregnancy compared to the optimal P 4 level.
Discussion
To the best of our knowledge, this study is the first in decades to explore the optimal luteal P 4 level following IVF and fresh embryo transfer.
The results of the present study suggest that low as well as high P 4 levels during the early and mid-luteal phases reduce the chance of a live birth during IVF treatment and fresh embryo transfer. In the early luteal phase (OPU + 2 or OPU + 3) the optimal range for P 4 was between 60 and 100 nmol/l, whereas the optimal P 4 level in the midluteal phase (OPU + 5) was 150-250 nmol/l.
Whether we looked at crude or adjusted OR, OR for positive hCG, clinical pregnancy or live birth or OR for reproductive outcomes in the early or mid-luteal phase, the pattern was distinctly the same. Thus, the probability of a positive reproductive outcome was reduced below and above the pre-defined optimal levels of P 4 .
The importance of luteal P 4 for the establishment and maintenance of pregnancy is undebatable, and it is well accepted that the success of an IVF cycle is crucially dependent upon a sufficient luteal phase support (Humaidan et al., 2005) . However, the optimal luteal P 4 level following IVF and fresh embryo transfer is poorly understood and did not receive much attention in recent years. Thus, there has been a lack of studies examining the optimal luteal P 4 levels in fresh embryo transfer cycles and therefore, a lack of defined P 4 thresholds to be used in the clinical setting. Consequently, luteal P 4 monitoring following fresh embryo transfer has not been implemented in standard IVF programs.
Several decades ago, numerous studies examined the early luteal P 4 profile following IVF treatment, correlating steroid levels to the chance of achieving a pregnancy (Balasch et al., 1995; Hassiakos et al., 1990; Howles et al., 1987; Liu et al., 1995) . However, all the mentioned studies compared luteal P 4 levels in pregnant versus non-pregnant patients assuming by default that the pregnant group would display a higher P 4 level than the non-pregnant group. These studies showed no differences in P 4 levels between groups and, therefore, concluded that luteal serum P 4 did not impact reproductive outcomes. However, bearing in mind the results of the present study, the comparison between luteal P 4 in pregnant versus non-pregnant patients is sub-optimal, as both very low and very high P 4 levels seem to reduce the chance of pregnancy. Consequently, the P 4 level in the non-pregnant group will consist of a mean of both very high and very low P 4 concentrations and will, therefore, be comparable to the P 4 level of the pregnant group, thus masking the true effect of different P 4 levels on the reproductive outcome.
A single recent study examined the mid-luteal P 4 levels in 595 patients following blastocyst transfer (Petersen et al., 2018) . As in the older studies, the P 4 levels in pregnant patients were compared to P 4 levels in non-pregnant patients, revealing comparable steroid levels. This led the authors to conclude that their data did not support the concept of an optimal P 4 range following IVF and fresh embryo transfer. However, with the present study we challenge this statement and emphasize that the true effect of high and low P 4 levels may be overlooked by the simple comparison between pregnant and non-pregnant patients as the association between luteal P 4 levels and pregnancy displays a non-linear pattern.
In the early Humaidan study, a very low mid-luteal P 4 level resulted in an early pregnancy loss of 79% (Humaidan et al., 2005) . Likewise, in the present study, the early pregnancy loss was significantly higher in the lower P 4 groups (<100 nmol/l) compared to the higher P 4 groups (>100 nmol/l). This suggests, that within the optimal range for early luteal P 4 levels (60-100 nmol/l), the high end (close to 100 nmol/l) may be more appropriate with regard to live birth compared to the low end (close to 60 nmol/l). The same is seen when looking at raw data from the early luteal phase. A similar pattern with a lower and higher P 4 threshold as seen in our study has been reported in both studies of non-human species (Nogueira et al., 2004) and following embryo transfer in human frozen-thawed cycles (Yovich et al., 2015) . Thus, it seems biologically plausible that thresholds exist for luteal P 4 inducing optimal endometrial receptivity in the fresh transfer cycle as well. The clinical consequence of 'too low' luteal P 4 levels could be to supply patients with additional exogenous P 4 in the attempt to 'rescue' endometrial maturation in time for embryo implantation. In contrast, patients with 'too high' luteal P 4 levels might be better off with segmentation and subsequent embryo transfer in a frozen-thawed cycle.
The key strengths of the present study include its prospective design, the large cohort of patients, the P 4 quantification in two separate periods of the luteal phase and the systematic approach to the handling of confounding factors. Using observational data, it is crucial to adequately address confounding in order to describe a valid causal association between exposure and outcome. Using DAGs, we systematically examined factors, which might introduce bias in the estimates of reproductive outcomes. By choosing this approach over the more traditional definition of confounding, we avoided the risk of colliderstratification bias with certain adjustments and were able to define the minimum set of factors to adjust for to remove the unwanted confounding in the final regression analysis (Howards, 2018) .
Important for the results, the same vaginal luteal support regimen was applied in all cycles. Thus, the serum P 4 level measured reflects the endogenous P 4 production in addition to the vaginal supplement in all participants. The observed optimal levels for P 4 were in line with the previously proposed lower threshold for P 4 (Yding Andersen and Vilbour Andersen, 2014) , and the optimal P 4 level was shifted upwards going from the early to the mid-luteal phase as would be expected from physiology. The participants included in the study were unselected broadening the generalizability of the findings. Moreover, the results seem to be applicable for both the GnRH agonist and the GnRH antagonist protocol as well as different ovulation trigger concepts.
It is well known that mid-luteal P 4 monitoring is challenged by the presence of fluctuations (Filicori et al., 1984) . However, in the early luteal phase, P 4 levels exhibit a non-pulsatile pattern in both the natural and stimulated cycle (OPU + 2) (Filicori et al., 1984; Tannus et al., 2017) . Furthermore, as previously demonstrated by our group, the magnitude of P 4 peaks in the mid-luteal phase (OPU + 7) following IVF and fresh embryo transfer is significantly correlated to the median P 4 level . Thus, very large P 4 fluctuations are predominantly seen in patients with a mid-luteal P 4 concentration exceeding 250 nmol/l whereas patients with P 4 levels <60 nmol/l display clinically stable P 4 values throughout the day. Consequently, a low P 4 value can be regarded as a 'true low value'-also when measured in the mid-luteal phase following IVF treatment. Thus, in the present study, the potential misclassification of mid-luteal P 4 measurements due to P 4 fluctuations would be a differentiated misclassification of exposure (Kesmodel, 2018) . In the present work, this misclassification type would take the estimate towards the null-value (no difference between groups) and, thus, lead to an underestimation of the true association between luteal P 4 levels and reproductive outcomes. Consequently, the significant decrease in reproductive outcomes seen in this study cannot be explained by information bias due to misclassification of exposure status.
Luteal P 4 monitoring in IVF cycles is a balance between the inconvenience of an additional procedure for the patient and the gain in terms of increased success rates. In the present study the combined prevalence of patients with low and high P 4 levels and, thus, patients with a potential need of treatment adjustment, was only 11% in the early luteal phase compared to 51% in the mid-luteal phase. Because all patients only had one blood sample drawn during luteal phase, we were not able to make a firm conclusion on the individual serum P 4 profiles going from the early to the mid-luteal phase. However, it seems that approximately 40% of patients will have either an insufficient P 4 increase from the early to the mid-luteal phase, thereby, ending in the low P 4 category (<150 nmol/l) on OPU + 5, or a too steep P 4 increase taking them into the high P 4 group (>400 nmol/l) on OPU + 5. Thus, P 4 monitoring in the early luteal phase may imply a risk of overlooking a substantial number of patients compared to mid-luteal monitoring.
Taken together, the optimal time for luteal P 4 monitoring seems to be a balance between pros and cons. Early luteal monitoring implies a high accuracy of P 4 measurements, and a theoretical possibility of increasing endometrial receptivity in low P 4 patients by use of additional exogenous P 4 , but also implies a low prevalence of patients in need of treatment adjustments. In contrast, mid-luteal monitoring detects a higher proportion of patients who require a change in treatment to succeed, but also implies a higher risk of P 4 fluctuations in the high P 4 group of patients. Furthermore, an intensified luteal phase support to low P 4 patients may be less efficient late in the cycle.
With this study, we hope to re-open the luteal phase discussion and to draw attention to the possibility of improving the reproductive outcomes of the fresh transfer IVF cycle. Thus, we suggest to move away from the 'one model fits all' and towards a more individualized luteal phase support policy. In recent years, much effort has been invested in the improvement of embryo culture techniques to obtain high blastulation rates. However, the present study suggests that in 51% of patients, high-quality blastocysts are transferred to a sub-optimal endometrial milieu. A disrupted luteal P 4 level seems to decrease the chance of live birth following blastocyst transfer with as much as 16 percentage points going from 54% in patients with optimal mid-luteal P 4 levels to 38% in patients with P 4 >400 nmol/l. Whether the 51% of patients with suboptimal P 4 levels would be better off with an adjustment of treatment-P 4 supplementation in case of low P 4 and segmentation in case of high P 4 levels-must be investigated in future RCTs.
In conclusion, our data suggest that the association between luteal P 4 levels and reproductive outcomes is non-linear-thus, both low as well as high luteal P 4 levels reduce the chance of a positive reproductive outcome. We hope that this study, which is the first in decades to explore the optimal luteal P 4 levels following IVF and fresh embryo transfer, will spark the interest of the topic and lead to future clinical trials within the research area.
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